About: Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1995 (uk) article scientifique publié en 1995 (fr) im November 1995 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1995 (en) artículu científicu espublizáu en payares de 1995 (ast) գիտական հոդված հրատարակված 1995 թվականի նոյեմբերի 1-ին (hy)
publication date	wds:Q71752227-B961CACA-80D4-4837-9712-5F484CE2B82C
publication date	1995-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71752227-4D24290C-0975-4E7E-BB92-58A5FA54A44F
language of work or name	English
author name string	wds:Q71752227-4DBE1BAD-2815-45F4-831B-1EF22B58EA8B wds:Q71752227-579EEB3A-AF9C-47C7-BD31-FED852AA8D06 wds:Q71752227-59EDD2B7-2C46-4F0C-825C-E9A2753DCBB1 wds:Q71752227-B17A601A-F913-4268-B972-815E51C5AEC9 wds:Q71752227-CFA7829E-D2DC-439F-9872-A16D82A9BE2C wds:Q71752227-E08CD3EB-2A2C-47FF-AD7D-D7DC40CFD38B wds:Q71752227-ED74D0C5-1306-4149-87CE-2AEFB666C39C
author name string	Y Chang H Lepor M J Barry K M Jones W O Williford M Machi E Walker-Corkery
rdfs:label	Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (en) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (nl)
skos:prefLabel	Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (en) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (nl)
name	Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (en) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (nl)
title	wds:Q71752227-1C0CD56F-1A50-41EA-A296-370785676495
title	Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? (en)
page(s)	wds:Q71752227-FA4257C0-6D0A-43E6-BA7F-317A29FBBF4A
page(s)	1770-1774
instance of	wds:Q71752227-23AAF60E-AFF2-4110-8661-9B293AD18672
instance of	scholarly article
main subject	wds:Q71752227-A553B0A4-5005-4C17-85C9-CDC771F1E63E
main subject	prostatic hypertrophy
PubMed ID	wds:Q71752227-C5641714-1E9F-4D4F-A082-5000BD866F43
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7563343
PubMed ID	7563343
published in	wds:Q71752227-5BEE586F-44FD-45CD-8568-EA19EA708DD1
published in	Journal of Urology
issue	wds:Q71752227-9B0EAA8C-FE91-4F49-A566-761E6D9527A0
volume	wds:Q71752227-FB3353FB-5901-4CC9-AB50-C37532F9A0C4
issue	5
volume	154
DOI	wds:Q71752227-B4C495B0-EF52-42D0-A369-560065ECB276
DOI	http://dx.doi.org/10.1016/S0022-5347(01)66780-6
DOI	10.1016/S0022-5347(01)66780-6
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71752227
is cites work of	Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia Comprehensive patient evaluation for benign prostatic hyperplasia The Clinical Benefits of Dutasteride Treatment for LUTS and BPH Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample Reproductive history and progression of lower urinary tract symptoms in women: results from a population-based cohort study Use of meta-analytic results to facilitate shared decision making Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial Benign prostatic hyperplasia. Part 2--management High-energy transurethral microwave thermotherapy in patients with acute urinary retention due to benign prostatic hyperplasia. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Surgical treatments for men with benign prostatic enlargement: cost effectiveness study Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Office evaluation of men with lower urinary tract symptoms Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group Impact of drug therapy on benign prostatic hyperplasia-specific quality of life Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity Determining the utility of recalled lower urinary tract symptoms Lower urinary tract symptoms in men. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials Alpha blockers for the treatment of benign prostatic hyperplasia. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study Self management for men with lower urinary tract symptoms: randomised controlled trial The development of lonidamine for benign prostatic hyperplasia and other indications. Treatment of benign prostatic hyperplasia in patients with cardiovascular disease Quality of life and alpha-blocker therapy: an important consideration for both the patient and the physician

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software